Opus Genetics, Inc.
As of Oct 22, 2026, Opus Genetics is in Stage 2, the uptrend phase, now in week 7 (since Sep 10, 2026). It closed at $3.82, 37.1% below its 52-week high and below its 200-day average, which is rising.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of t… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is IRD early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
IRD among Biotechnology47th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …47 | IRD | Stage 2 · wk 7 | 94 | −20.9% |
Opus Genetics: quick answers
What stage is Opus Genetics in?
As of Oct 22, 2026, Opus Genetics (IRD) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 10, 2026 and is in week 7. What the four stages mean
Is Opus Genetics in an uptrend?
Yes. Opus Genetics is in a Stage 2 uptrend. It trades 7.7% below its 200-day average, which is rising.
How far is Opus Genetics from its 52-week high?
Opus Genetics closed at $3.82 on Oct 22, 2026, 37.1% below its 52-week high of $6.07. Its 52-week low is $1.74.
How has Opus Genetics performed over the past year?
As of Oct 22, 2026, Opus Genetics is up 90.0% over the past year and up 80.2% so far in 2026.
Which sector and industry is Opus Genetics in?
Opus Genetics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.